[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Rocha Filho FD, Lima GG, Ferreira FV, Lima MG, Hissa MN: Orbital metastasis as primary clinical manifestation of thyroid carcinoma--case report and literature review. Arq Bras Endocrinol Metabol; 2008 Dec;52(9):1497-500
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis as primary clinical manifestation of thyroid carcinoma--case report and literature review.
  • Capillary thyroid carcinoma (PTC) is the most common neoplasm of thyroid.
  • Metastatic thyroid carcinoma rarely involves the orbit.
  • We reported an uncommon case of orbital metastasis of PTC.
  • The biopsy of the tumor in orbit revealed metastatic thyroid carcinoma.
  • Currently, the patient has been receiving palliative chemotherapy with Clodronate Disodium.
  • Although rare, thyroid carcinoma should be suspected in orbit metastasis.
  • [MeSH-major] Carcinoma, Papillary / secondary. Orbital Neoplasms / secondary. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197459.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 19
  •  go-up   go-down


2. Asproudis I, Gorezis S, Aspiotis M, Tsanou E, Kitsiou E, Merminga E, Peschos D, Charalabopoulos K, Agnantis NJ: Orbital metastasis from verrucous carcinoma of the oral cavity: case report and review of the literature. In Vivo; 2007 Sep-Oct;21(5):909-12
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis from verrucous carcinoma of the oral cavity: case report and review of the literature.
  • A rare case of metastatic verrucous carcinoma (VC) of the oral cavity is presented.
  • The patient reported history of diagnosis of verrucous squamous carcinoma in the oral cavity occuring 6 years earlier that although excised presented several recurrences.
  • The lesion metastasized to local lymph nodes and after being characterized as inoperable the patient underwent thirty-seven sessions of radiation therapy.
  • Two months after completion of radiation therapy, the patient underwent an orbital CT scan that revealed a mass with morphological features consistent with secondary involvement of the orbit from the known VC.
  • Although treated with chemotherapy, the patient died 5 months later.
  • No other case of this entity, which usually presents as a slow-growing lesion enlarging with direct extension rather than frank invasion, metastasizing to the orbit has been reported in relevant literature.
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019435.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 15
  •  go-up   go-down


3. Kaur H, Buettner H, Salomao DR, Marks RS: Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma. Am J Ophthalmol; 2007 Feb;143(2):369-70
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
  • PURPOSE: To report transcleral orbital invasion by a radiation- and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
  • METHODS: A 51-year-old female was found to have choroidal metastasis from a previously unknown primary pulmonary adenocarcinoma.
  • She underwent external beam radiation treatment with a total dose of 40 Gray (Gy), delivered in 20 fractions over 28 days, followed by adjuvant chemotherapy with gemcitabine and carboplatin.
  • After completing two of the three scheduled chemotherapy cycles, the choroidal lesion was observed to have increased in size.
  • RESULTS: A transvitreal aspiration biopsy of the choroidal lesion confirmed the diagnosis of metastatic pulmonary adenocarcinoma.
  • Histopathology revealed invasion through scleral emissary channels to the retrobulbar tissue and through the optic nerve substance itself.
  • CONCLUSIONS: Despite appropriate external beam radiation therapy (EBRT) and chemotherapy, pulmonary adenocarcinoma metastases to the choroid can continue to grow and may invade the orbit transclerally.
  • [MeSH-major] Adenocarcinoma / secondary. Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Orbital Neoplasms / pathology. Sclera / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance. Eye Enucleation. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiation Tolerance. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258542.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Gerencer RZ, Patel U, Hunter C, Heffernan JT: The role of endoscopic sinus surgery in the diagnosis and treatment of metastatic orbital carcinoid tumors. Ear Nose Throat J; 2007 Mar;86(3):157-61
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of endoscopic sinus surgery in the diagnosis and treatment of metastatic orbital carcinoid tumors.
  • Carcinoid tumor metastatic to the orbit is a rare occurrence.
  • We report such a case in a patient with a carcinoid metastasis that was found in the medial rectus muscle.
  • The diagnosis was established via a transnasal endoscopic approach.
  • We also discuss the treatment of metastatic orbital carcinoid in the hope that we will increase awareness of the utility of transnasal endoscopy in facilitating both the diagnosis and treatment of posteromedial orbital pathology.
  • [MeSH-major] Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Endoscopy / methods. Orbital Neoplasms / secondary. Orbital Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427777.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Bartley GB, Campbell RJ, Salomão DR, Bradley EA, Marsh WR, Bite U: Adrenocortical carcinoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2001 May;17(3):215-20
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma metastatic to the orbit.
  • PURPOSE: To describe the clinical course and histopathologic features of a patient with adrenocortical carcinoma metastatic to the orbit.
  • Several metastases ensued, including a large tumor to the right superior lateral bony orbit with extension to the brain, temporalis fossa, and orbit proper.
  • The tumor was resected with the use of a combined neurosurgical, ophthalmic, and craniofacial approach.
  • The patient died of widespread metastatic disease 15 months after the orbital operation.
  • CONCLUSIONS: Metastasis to the orbit from adrenocortical carcinoma is rare.
  • Surgical resection is the treatment of choice, with adjunctive radiation therapy and chemotherapy in some cases.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / secondary. Orbital Neoplasms / secondary
  • [MeSH-minor] Adrenalectomy. Adult. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11388389.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Baroody M, Hartstein ME, Holds JB: Immunotherapy for melanoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2003 Jul;19(4):270-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy for melanoma metastatic to the orbit.
  • PURPOSE: To present 3 cases of melanoma metastatic to the orbit treated with various traditional modalities including surgery and chemotherapy and being treated with melanoma vaccines and to present background information on immunotherapy.
  • METHODS: Retrospective review of 3 patients with melanoma metastatic to the orbit who were treated with melanoma vaccines along with conventional treatments.
  • One patient had known orbital involvement before vaccine treatment; 2 patients had orbital metastases subsequent to vaccine administration.
  • RESULTS: Patients survived at least 13 months after the diagnosis of metastatic melanoma, with 1 patient surviving 51 months after the onset of metastases and administration of melanoma vaccine.
  • CONCLUSIONS: Although still unproven, immunotherapy with melanoma vaccines is a promising new treatment modality for metastatic melanoma with few side effects.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy. Melanoma / secondary. Melanoma / therapy. Orbital Neoplasms / secondary. Orbital Neoplasms / therapy
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Female. Humans. Male. Neoplasm Proteins / immunology. Orbit / radiography. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12878874.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Neoplasm Proteins
  •  go-up   go-down


7. Dunkel IJ, Khakoo Y, Kernan NA, Gershon T, Gilheeney S, Lyden DC, Wolden SL, Orjuela M, Gardner SL, Abramson DH: Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer; 2010 Jul 15;55(1):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.
  • BACKGROUND: We previously reported promising pilot results treating patients with stage 4a metastatic retinoblastoma with combined intensive conventional chemotherapy, high-dose chemotherapy with autologous hematopoietic stem cell rescue, and radiation therapy and now present an expanded and updated series.
  • PROCEDURE: Fifteen patients with bone marrow (n = 14), bone (n = 10), orbit (n = 9), and/or liver (n = 4) disease were treated.
  • Induction chemotherapy usually consisted of vincristine, cyclophosphamide, cisplatin, and etoposide.
  • The high-dose chemotherapy regimen included carboplatin and thiotepa alone (n = 1) or with etoposide (n = 5) or topotecan (n = 7).
  • RESULTS: Bone marrow cleared at first post-initiation of chemotherapy examination in all patients and stem cells were harvested after a median of 3.5 cycles of chemotherapy (range 3-6 cycles).
  • Two patients progressed prior to high-dose chemotherapy and died.
  • Thirteen received high-dose chemotherapy at a median of 6 months post-diagnosis of metastases (range 4-8 months).
  • Ten are retinoblastoma-free in first remission at a median follow-up of 103 months (range 34-202 months) while three recurred (two in the CNS, one in the mandible) 14-20 months post-diagnosis of metastases.
  • Six of the 10 survivors received radiation therapy.
  • Three patients developed secondary osteosarcoma 14, 4, and 9 years after diagnosis of metastatic disease.
  • CONCLUSIONS: Intensive multimodality therapy including high-dose chemotherapy with autologous hematopoietic stem cell rescue was curative for the majority of patients with stage 4a metastatic retinoblastoma treated.
  • The contribution of external beam radiation therapy is unclear.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Retinal Neoplasms / secondary. Retinal Neoplasms / therapy. Retinoblastoma / secondary. Retinoblastoma / therapy
  • [MeSH-minor] Child, Preschool. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Neoplasm Staging. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486171.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Odashiro AN, Leite LV, Oliveira RS, Tamashiro C, Pereira PR, Miiji LN, Odashiro DN, Burnier MN Jr: Primary orbital mesenchymal chondrosarcoma: a case report and literature review. Int Ophthalmol; 2009 Jun;29(3):173-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary orbital mesenchymal chondrosarcoma: a case report and literature review.
  • It is an aggressive neoplasm with a high tendency for late recurrence and occasional delayed distant metastasis.
  • Orbital MC is very rare, and only approximately 30 cases have been described in the literature.
  • We describe here one case of primary orbital MC.
  • Computed tomography (CT) scans of the orbit revealed a right intraconic lesion, with areas of calcification.
  • Histopathological analysis revealed that the tumor had a biphasic pattern, showing a combination of small cell malignancy and well-differentiated cartilage.
  • The patient received chemotherapy, and no metastatic disease was found at the 2-month follow-up.
  • CONCLUSION: Although rare, MC should be considered in the differential diagnosis of a well-circumscribed orbital lesion in young adults, especially when CT scans reveal areas of calcification within the tumor.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, CD99. Calcinosis / diagnosis. Cartilage / metabolism. Cartilage / pathology. Cell Adhesion Molecules / analysis. Cell Adhesion Molecules / biosynthesis. Diagnosis, Differential. Drug Therapy. Humans. Immunohistochemistry. Male. Mesenchymal Stromal Cells / metabolism. Mesenchymal Stromal Cells / pathology. S100 Proteins / analysis. S100 Proteins / biosynthesis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1999 Jul;52(1):50-3 [10390173.001]
  • [Cites] Histopathology. 2006 Jan;48(2):201-3 [16405671.001]
  • [Cites] Cancer. 1971 Sep;28(3):605-15 [5096926.001]
  • [Cites] Neuroradiology. 1997 Apr;39(4):296-301 [9144681.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Sep-Oct;22(5):378-82 [16985424.001]
  • [Cites] Skeletal Radiol. 2005 Dec;34(12 ):785-92 [16211384.001]
  • [Cites] Radiol Clin North Am. 1999 Jan;37(1):203-17, xii [10026739.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):192-204 [17284103.001]
  • [Cites] Laryngoscope. 2003 May;113(5):783-90 [12792311.001]
  • [Cites] Ophthalmology. 2004 May;111(5):1016-22 [15121382.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1253-5 [1636546.001]
  • [Cites] Cancer. 1986 Jun 15;57(12 ):2444-53 [3697943.001]
  • [Cites] Cancer. 1959 Nov-Dec;12:1142-57 [14416919.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1088-94 [15731776.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):263-9 [12673561.001]
  • (PMID = 18188507.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / S100 Proteins
  •  go-up   go-down


9. Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N: Metastatic retinoblastoma clinical features, treatment, and prognosis. Ophthalmology; 2006 Sep;113(9):1558-66
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic retinoblastoma clinical features, treatment, and prognosis.
  • PURPOSE: To evaluate the clinical features, treatment, and prognosis in patients with metastatic retinoblastoma.
  • PARTICIPANTS: Eighteen consecutive patients with metastatic retinoblastoma who were diagnosed and managed at the Oncology Service of Ankara University, Turkey, between January 1999 and January 2005.
  • METHODS: All patients underwent magnetic resonance imaging (MRI) of the orbit and brain, lumbar puncture, bone marrow aspiration, and bone scintigraphy for metastatic evaluation.
  • Histopathologic confirmation of retinoblastoma via enucleation, exenteration, or orbital biopsy was obtained in each patient.
  • Systemic treatment for metastatic retinoblastoma consisted of chemotherapy and radiotherapy (craniospinal, orbital, or both), if necessary.
  • MAIN OUTCOME MEASURES: Status of extraocular spread, site of metastasis, and survival from metastatic retinoblastoma.
  • All patients with metastatic retinoblastoma had histopathologic or MRI evidence of unilateral extraocular disease characterized by optic nerve involvement, extrascleral extension, or both.
  • Nine of 18 patients experienced central nervous system (CNS) involvement, 5 patients had distant and CNS metastasis, and 4 patients had distant metastasis only.
  • Fourteen patients underwent craniospinal irradiation and 12 had orbital irradiation.
  • At a mean follow-up of 24 months (range, 4-62), all patients with CNS and concurrent distant and CNS metastasis were deceased.
  • Four patients who had distant metastasis only were alive at a follow-up ranging from 9 to 62 months.
  • CONCLUSIONS: The prognosis for metastatic retinoblastoma is dismal and the presence of CNS involvement may portend an even worse outcome.
  • [MeSH-major] Retinal Neoplasms / pathology. Retinal Neoplasms / therapy. Retinoblastoma / secondary. Retinoblastoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Child. Child, Preschool. Eye Enucleation. Eye Evisceration. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Optic Nerve Neoplasms / mortality. Optic Nerve Neoplasms / secondary. Optic Nerve Neoplasms / therapy. Orbital Neoplasms / mortality. Orbital Neoplasms / secondary. Orbital Neoplasms / therapy. Prognosis. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828510.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Font RL, Ray R, Mazow ML, Del Valle M: Mesenchymal chondrosarcoma of the orbit: a unique radiologic-pathologic correlation. Ophthal Plast Reconstr Surg; 2009 May-Jun;25(3):219-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma of the orbit: a unique radiologic-pathologic correlation.
  • PURPOSE: To report a unique radiologic-histopathologic correlation of mesenchymal chondrosarcoma of the orbit in a 24-year-old Asian woman.
  • CT showed a left orbital mass depicting a central radiolucent, nonenhancing component, and a denser peripheral enhancing portion.
  • Histopathologic examination of the orbital mass showed a biphasic pattern of a mesenchymal chondrosarcoma exhibiting features of a high-grade sarcoma with hemangiopericytoma pattern that corresponds to the radiopaque portion of the mass and areas of chondrosarcoma that correlated with the radiolucent component of the tumor.
  • The patient underwent exenteration of the left orbit followed by radiotherapy and chemotherapy.
  • The last follow-up (8 years, 1 month) disclosed no evidence of recurrence or metastatic disease.
  • The authors believe that recognizing the different radiologic features of the orbital tumor can help clinicians in establishing the correct preoperative diagnosis of this potentially lethal neoplasm.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Orbital Neoplasms / pathology. Orbital Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Exophthalmos / etiology. Exophthalmos / radiography. Female. Follow-Up Studies. Humans. Orbit Evisceration. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454935.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Chastagner P: [Malignant extraconal tumors of the orbit in childhood]. Neurochirurgie; 2010 Apr-Jun;56(2-3):281-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant extraconal tumors of the orbit in childhood].
  • [Transliterated title] Les tumeurs malignes extraconiques de l'orbite chez l'enfant.
  • Malignant extraconal orbital tumors are very rare during childhood and must be referred as soon as possible to a highly specialized center to be managed by a multidisciplinary team.
  • Both diagnosis and treatment must be undertaken as soon as possible.
  • The course of these malignant tumors can be acute and can jeopardize the function of the eye or be life-threatening, especially in the event of metastatic locations.
  • Sometimes diagnosis should be clear with the association of an orbital tumor and deterioration of the general health status favoring metastatic disease.
  • Most metastatic neuroblastomas present such clinical symptoms in young children.
  • Today both CT and MRI are highly valuable in assessing the diagnosis and starting the management of these tumors.
  • Biopsy is mandatory to confirm the diagnosis.
  • Among the primitive tumors, soft tissue sarcomas, especially rhabdomyosarcomas, are the most frequent.
  • The diagnosis is suggested when the onset of the disease is acute and the course is rapid.
  • Most respond to neoadjuvant chemotherapy.
  • In the event of a residual tumor, local treatment is indicated so that surgery and/or radiotherapy are used as second-line treatment.
  • It can be satisfactory (Langerhans' cell histiocytosis, lymphoma, meningioma, infantile fibrosarcoma) or poor (metastatic tumor, rhabdoid tumor).
  • [MeSH-major] Orbital Neoplasms / pathology. Orbital Neoplasms / surgery
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Exophthalmos / etiology. France. Humans. Incidence. Infant. Male. Neoplasm Metastasis. Prognosis. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20303550.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Chew R: Destruction of the orbit and globe by recurrence of basal cell carcinoma. Optometry; 2007 Jul;78(7):344-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Destruction of the orbit and globe by recurrence of basal cell carcinoma.
  • Several treatment options exist, including surgical excision, cryotherapy, radiotherapy, laser surgery, chemotherapy, and photodynamic therapy.
  • The average rate of recurrence is 5%, depending on the type of BCC, the size, the location, and therapeutic approach.
  • At that time the patient was treated with surgical excision and radiotherapy.
  • They found that the BCC had infiltrated the right globe and the retro-orbital region and probably invaded the adjacent bony margins.
  • He had extensive surgery to remove the tumor and subsequent skin grafting.
  • However, there is no procedure that has a zero recurrence rate.
  • BCC, although rarely metastatic, can be invasive.
  • This case underscores the importance of proper follow-up protocol for all surgical patients as well as patient education that reinforces the importance of follow-up care and self-monitoring on the part of the patient.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Orbit / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601572.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kuo SC, Hsiao SC, Chiou CC, Chen FF, Huang KC: Metastatic carcinoma of the breast: a case with the unusual presentation of unilateral periorbital edema. Jpn J Ophthalmol; 2008 Jul-Aug;52(4):305-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinoma of the breast: a case with the unusual presentation of unilateral periorbital edema.
  • BACKGROUND: Metastasis of mammary cancer involving the orbit is common, and it typically presents with enophthalmos and restrictions of ocular motility.
  • CASE: Metastasis of breast cancer involving unilateral eyelid edema was diagnosed in a 66-year-old woman.
  • The diagnosis was based on the histopathologic features of carcinomatous cells in the excised specimen.
  • OBSERVATIONS: Insidious, progressive unilateral upper and lower eyelid swelling of the right eye disappeared after one cycle of palliative chemotherapy.
  • Neither restriction nor proptosis developed in the whole course.
  • CONCLUSIONS: Possible metastasis should be considered as a possible etiology of unilateral eyelid edema, even without a palpable mass or limitation of ocular motility.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Edema / diagnosis. Eyelid Diseases / diagnosis. Orbital Neoplasms / secondary
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cyclophosphamide / administration & dosage. Female. Humans. Keratins / analysis. Magnetic Resonance Imaging. Neoplasm Proteins / analysis. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jan;18(1):84-8 [11910331.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1998 Sep;14(5):323-7 [9783282.001]
  • [Cites] Postgrad Med. 1999 Apr;105(4):45-6 [10223085.001]
  • [Cites] Ophthalmology. 1998 Oct;105(10):1897-901 [9787361.001]
  • [Cites] Arch Ophthalmol. 2000 Feb;118(2):227-32 [10676788.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Sep;17 (5):346-54 [11642491.001]
  • [Cites] Exp Oncol. 2004 Sep;26(3):246-8 [15494697.001]
  • [Cites] Curr Opin Ophthalmol. 2007 Sep;18(5):398-401 [17700233.001]
  • [Cites] Plast Reconstr Surg. 2005 Jan;115(1):22-30 [15622227.001]
  • [Cites] Arch Ophthalmol. 2007 Dec;125(12):1668-73 [18071120.001]
  • [Cites] Acta Ophthalmol Scand. 2007 Mar;85(2):133-42 [17305726.001]
  • [Cites] J Am Acad Dermatol. 1995 Aug;33(2 Pt 1):161-82; quiz 183-6 [7622642.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Feb;81(1):47-50 [12631019.001]
  • (PMID = 18773269.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Taxoids; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 68238-35-7 / Keratins; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab
  •  go-up   go-down


14. Schick U, Lermen O, Hassler W: Management of orbital metastases. Zentralbl Neurochir; 2006 Feb;67(1):1-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of orbital metastases.
  • True metastatic disease to the orbit is rare.
  • We present an overview of the treatment and clinical outcome of 11 orbital metastases, carried out in our center from 1995 to 2002.
  • The surgical approach was determined by the location and type of the lesion.
  • The most common primary cancers that metastasized to the orbit were lung cancer, and breast cancer.
  • Three patients showed recurrent tumor growth despite chemo- and/or radiotherapy.
  • The mean survival time was 15 months after diagnosis of orbital metastases.
  • A multidisciplinary treatment is required.
  • Therapeutic options include surgical biopsy, debulking or excision, hormonal therapy, chemotherapy, and radiation therapy.
  • [MeSH-major] Neurosurgical Procedures. Orbital Neoplasms / secondary. Orbital Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518744.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Luh JY, Han ES, Simmons JR, Whitehead RP: Poorly differentiated colon carcinoma with neuroendocrine features presenting with hypercalcemia and cutaneous metastases: case report and review of the literature. Am J Clin Oncol; 2002 Apr;25(2):160-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A poorly differentiated colon carcinoma with neuroendocrine features occurred in a 42-year-old patient with metastases to the liver, both femurs, left orbit, and scalp.
  • The hypercalcemia was caused by the expression of a parathyroid hormone related peptide by both the primary and cutaneous metastatic tumors.
  • Bisphosphonate treatment helped normalize serum calcium in a few days, but hypercalcemia recurred approximately 3 weeks later.
  • Chemotherapy only mildly reduced the size of the cutaneous metastases.
  • The patient died 8 months after initial diagnosis.
  • Hypercalcemia and cutaneous metastases are separately associated with a poor prognosis and indicate advanced and widely metastatic disease.
  • [MeSH-major] Carcinoma / secondary. Colonic Neoplasms / pathology. Hypercalcemia / etiology. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Fatal Outcome. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Neoplasm Proteins / metabolism. Parathyroid Hormone-Related Protein. Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11943894.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PTHLH protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / Proteins
  • [Number-of-references] 24
  •  go-up   go-down


16. Gorelick J, Ross D, Marentette L, Blaivas M: Sinonasal undifferentiated carcinoma: case series and review of the literature. Neurosurgery; 2000 Sep;47(3):750-4; discussion 754-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SNUC tends to present with advanced-stage disease, often with intracranial invasion, and requires an aggressive treatment approach that includes surgical resection.
  • CLINICAL PRESENTATION: Four patients presented with various symptoms related to the nose and/or orbit, including one or more of the following: obstruction, epistaxis, decreased visual acuity, diplopia, and pain.
  • INTERVENTION: All four patients underwent multimodal treatment with chemotherapy, radiotherapy (60-65 Gy), and aggressive surgical resection via a combined bifrontal craniotomy and a subcranial approach to the anterior cranial fossa.
  • Three of four patients died as a result of their disease, an average of 15 months after diagnosis.
  • Only one patient remains alive, although with metastatic intracranial disease, at 24 months after diagnosis.
  • CONCLUSION: SNUC is a rare neoplasm with a poor prognosis despite an aggressive multimodal approach to treatment.
  • On the basis of our experience, we advocate radical resection as part of the initial combined therapy for patients who present with locally advanced, nonmetastatic disease but we suggest reserving surgery for patients with early brain invasion until there has been a radiographically proven central nervous system response to adjuvant therapy.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10981763.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 16
  •  go-up   go-down


17. Kokufu I, Tanei T, Taniguchi H, Kimura F, Fukuda K, Yamamoto M, Yano T, Yamada K, Tamaoka K, Hosono M: [Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer]. Gan To Kagaku Ryoho; 2003 Jan;30(1):111-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer].
  • We report two cases in which weekly paclitaxel (TXL) administration and concurrent radiation was effective for metastatic breast cancer.
  • Case 1: A 50-year-old woman was found to have atelectasis of the middle lobe after treatment for brain metastasis.
  • The metastatic lymph nodes had disappeared one month after the treatment.
  • Case 2: A 31-year-old woman was diagnosed with advanced breast cancer with lung, pleural, bone and orbital metastases.
  • She received weekly TXL administration and concurrent radiation to the orbit.
  • The lung and pleural metastases had disappeared and the orbital metastasis was decreased by 75% one month after the treatment, and the case was assessed as a partial response.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12557714.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Castro Alonso FJ, Carbonell Ruiz P, Palomar Gómez A: [Acute proptosis as first symptom of a lung carcinoma]. Arch Soc Esp Oftalmol; 2000 Mar;75(3):195-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Proptosis aguda como primera manifestación de un carcinoma de pulmón.
  • PURPOSE/METHOD: We present the case of a 57-year-old patient who was visited in our ophthalmology department complaining of acute right ocular proptosis, fever and malaise.
  • The clinical, ophthalmic and radiologic examination showed the presence of an extraconal orbital tumor as the cause of this exophthalmos.
  • RESULTS/CONCLUSION: Further complementary studies revealed a small cell carcinoma of the lung metastatic to the right orbit.
  • We report the excellent response to chemotherapy both of the primary lung neoplasm and the orbital metastasis.
  • [MeSH-major] Exophthalmos / etiology. Lung Neoplasms / pathology. Orbital Neoplasms / secondary
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11151149.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


19. Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT: Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology; 2000 Dec;107(12):2250-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: The two main outcome measures were ultimate patient management and the development of retinoblastoma metastasis.
  • RESULTS: Of more than 900 consecutive patients with retinoblastoma managed on the Ocular Oncology Service at Wills Eye Hospital in Philadelphia, 11 (1%) had prior vitrectomy in an eye with viable tumor before referral to us for suspected retinoblastoma.
  • Anterior chamber tumor cells were clinically visible in four eyes (36%), hyphema in two eyes (18%), and iris neovascularization in two eyes (18%).
  • Adjuvant treatment was delivered in 10 patients (91%), using orbital radiotherapy in nine patients (82%) and chemotherapy in nine patients (82%).
  • The vitrectomy ports, Tenon's fascia, cut end of the optic nerve, and orbit were free of tumor.
  • Of the 10 patients who received prophylactic chemotherapy, radiotherapy, or both in addition to enucleation for prevention of retinoblastoma metastasis, none (0%) experienced metastasis or orbital recurrence during the mean follow-up of 7 years (range, 0.2-24 years) from the time of retinoblastoma diagnosis.
  • However, one patient was referred to us after the development of metastatic retinoblastoma, and despite aggressive chemotherapy and radiotherapy after enucleation, died 24 months later.
  • If vitrectomy is performed in an eye with unsuspected retinoblastoma, enucleation combined with adjuvant chemotherapy, radiotherapy, or both without delay is advised to prevent systemic tumor dissemination.
  • [MeSH-major] Retinal Neoplasms / diagnosis. Retinoblastoma / diagnosis. Vitrectomy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Endophthalmitis / surgery. Eye Enucleation. Eye Infections, Parasitic / surgery. Female. Humans. Male. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Vitreous Hemorrhage / surgery

  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11097606.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Mozet C, Stumpp P, Mekonnen B, Dietz A: [Therapeutic options in sinunasal adenoid cystic carcinomas--a case report and review]. Laryngorhinootologie; 2009 Oct;88(10):631-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options in sinunasal adenoid cystic carcinomas--a case report and review].
  • [Transliterated title] Behandlungsstrategie bei sinunasalen adenoidzystischen Karzinomen--Ein Fall mit Literaturübersicht.
  • We discuss both, surgical margins and functional results preoperatively and postoperative options for adjuvant therapy.
  • The former opinion of a resistance of ACC towards chemotherapy or irradiation seems to be outdated, even though consensus about therapeutic strategies is still missing.
  • MATERIAL AND METHODS: We discuss therapeutic options and compare data from literature regarding the best adjuvant therapy with the case of a 25-year-old patient with an advanced ACC of the left fossa pterygopalatina.
  • Further we discuss alternative therapeutic options like neutron irradiation, chemotherapy or targeted therapy.
  • Following the advice from literature, we performed an eye saving tumor resection by a left transmaxilloethmoidale sphenoidectomy via combined trans- und extranasal approach.
  • RESULTS: With the described therapeutic strategy we reached an optimal local tumor control with unlimited visus and without functional and cosmetic restrictions up to now.
  • Periodic staging did not show any local tumor progress or metastatic spread hitherto.
  • CONCLUSION: Organ preserving surgery and adjuvant radiochemotherapy even in combination with taxol and carboplatin seems to be a sufficient therapeutic option in treating advanced sinunasal ACC, and might not have any prognostic disadvantages to radical surgery.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Neoplasm, Residual / surgery. Paranasal Sinus Neoplasms / surgery. Pterygopalatine Fossa / surgery. Skull Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Endoscopy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Orbit / pathology. Orbit / surgery. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Sphenoid Bone / pathology. Sphenoid Bone / surgery. Surgery, Computer-Assisted. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19813159.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 51
  •  go-up   go-down


21. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96.
  • All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1.
  • All received postoperative chemotherapy.
  • With RT: 10/12 patients are in first complete remission; 2/12 had a metastatic relapse (1 also local relapse), and both of them died of disease.
  • Without RT: 16/27 maintained the first complete remission, however 1/16 died due to a second tumor; 8 suffered from local relapse (4 pelvic, 1 orbit, 1 vagina, 1 head-neck-non-parameningeal, 1 abdomen) and 3 of them died, 3 showed a metastatic recurrence (2 extremities, 1 pelvic) and 1 died.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Sarcoma

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Hallacq P, Labrousse F, Roullet B, Orsel S, Bessede JP, Moreau JJ: [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature]. Neurochirurgie; 2001 Dec;47(6):542-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinomes adénoïdes kystiques envahissant la base du crâne. A propos de 4 observations et revue de la littérature.
  • Neurosurgical decision making is not well defined regarding the extent of intracranial tumor component removal, as neurosurgical expertise is limited for this peculiar type of tumors.
  • One patient with advanced metastatic disease was submitted to chemotherapy.
  • Three patients died from local tumor progression and distant metastases within three years after the intracranial tumor extension has been diagnosed.
  • The patient with an ethmoid tumor is still alive seven years after surgery without any evidence of local tumor progression nor distant metastases.
  • Surgery remains the gold standard treatment for adenoid cystic carcinomas invading the skull base.
  • However, in our opinion a large tumor removal, without or with bone osteotomies, but without sacrifice of cranial nerves, cavernous sinus, internal carotid artery, and of the orbit allows patient survival with an acceptable comfort and absence of psychological distress due to disfigurating surgery nor surgically induced neurological functional deficit.
  • The place of chemotherapy has, yet, to be determined.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915613.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J: Low PSA metastatic androgen- independent prostate cancer. Eur Urol; 2000 Sep;38(3):250-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low PSA metastatic androgen- independent prostate cancer.
  • OBJECTIVES: To describe the clinical parameters of low PSA, progressive metastatic androgen-independent prostate cancer.
  • Patients received cisplatin-based therapy.
  • Specimens from the primary tumor were reviewed and neuroendocrine differentiation was determined with chromogranin-A and neuron-specific enolase immunocytochemical staining.
  • Metastases involved bone in 11 patients (61.1%) - 5 (27.7%) blastic, 2 (11.1%) lytic, and 4 (22.2%) combined - liver in 10 patients (55.5%), lymph nodes in 8 (44.4%), and lung in 6 (33.3%); solitary sites as orbit, skin and spleen were noted as well.
  • Of the 12 patients who consented to chemotherapy, 8 (66.6%) achieved an objective response (95% CI, 34.
  • CONCLUSIONS: Progressive androgen-independent prostate cancer with low serum PSA is characterized by visceral metastases, high proportion of lytic bone disease, sensitivity to cisplatin-based chemotherapy, and histological features of small cell or poorly differentiated prostate cancer.
  • In this subgroup of patients, selection of the therapeutic approach can be based on clinical parameters.
  • The rise of the serum markers may aid in the diagnosis and follow-up of these patients.
  • [MeSH-minor] Androgens. Humans. Male. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies


24. van der Zee J, Koper PC, Jansen RF, de Winter KA, van Rhoon GC: Re-irradiation and hyperthermia for recurrent breast cancer in the orbital region: a case report. Int J Hyperthermia; 2004 Feb;20(1):1-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-irradiation and hyperthermia for recurrent breast cancer in the orbital region: a case report.
  • Based on the good results of re-irradiation plus hyperthermia in breast cancer recurrences on the chest wall, it was decided to offer similar treatment to a patient with recurrent metastatic breast cancer in the orbital region.
  • She was treated with six neo-adjuvant chemotherapy courses and mastectomy, followed by hormonal treatment.
  • In December 1998, she was diagnosed with metastatic disease in the medial upper quadrant of the left orbit.
  • This was excised, followed by 40 Gy radiotherapy.
  • Nine months later, the tumour had recurred in the left orbit at the margin of the radiotherapy field.
  • This again was treated with surgery, followed by 30 Gy radiotherapy.
  • Two months thereafter, the eyelid tumour progressed and hormonal therapy was changed, without an effect on the eyelid tumour.
  • Screening gave no evidence of tumour activity elsewhere.
  • The patient preferred treatment with re-irradiation plus hyperthermia to a surgical approach.
  • Eight fractions of 4 Gy were given in 4 weeks, combined with once weekly hyperthermia.
  • One week after treatment, the tumour had regressed completely.
  • The patient died 22 months following treatment.
  • On examination, there was epilation of the eyelids, a slight conjunctival oedema, no subcutaneous fibrosis and no evidence of tumour regrowth.
  • Toxicity of re-irradiation plus hyperthermia might lead to either a loss of vision or a delayed loss of her left eye due to treatment-induced toxicity.
  • The chosen local treatment resulted in a very good palliative effect, which lasted for the patient's remaining lifetime of 22 months.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / therapy. Eyelid Neoplasms / radiotherapy. Eyelid Neoplasms / therapy. Hyperthermia, Induced. Radiotherapy, High-Energy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14612310.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Valenzuela AA, Archibald CW, Fleming B, Ong L, O'Donnell B, Crompton J J, Selva D, McNab AA, Sullivan TJ: Orbital metastasis: clinical features, management and outcome. Orbit; 2009;28(2-3):153-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis: clinical features, management and outcome.
  • PURPOSE: To review the clinical features, treatment, outcome and survival of metastatic tumors of the orbit.
  • MATERIALS AND METHODS: Retrospective, non-comparative, chart review of 80 patients with orbital metastasis treated in four tertiary orbital centres in Australia.
  • Orbital involvement commonly presented late in a multisystemic disease; however, the orbit was the first presentation in 15% of the cases.
  • Computed tomography commonly showed a solid enhancing mass (42 cases) located within the orbital fat (43%), or enlarging an extraocular muscle (28%).
  • Breast carcinoma (29%), melanoma (20%), and prostatic cancer (13%) were the most frequent histological types.
  • Treatment was often multi-disciplinary and modalities included radiotherapy, chemotherapy, hormone therapy, surgery, and immunotherapy.
  • Survival was limited to 1.5 years after diagnosis independent of the histological type, with 29% of patients alive after 17 months follow-up.
  • CONCLUSIONS: A high index of suspicion and appropriate intervention with histological diagnosis can help in the management and quality of life in patients with metastatic orbital disease.
  • Overall survival is limited and we encountered statistical limitations proving differences in the survival based on the sub-type of primary tumour involved.
  • Metastatic orbital melanoma presented a higher incidence when compared with previous studies, probably due to the increase frequency of skin found in the Australian population.
  • [MeSH-major] Cause of Death. Orbital Neoplasms / secondary. Orbital Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Australia. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Female. Humans. Immunohistochemistry. Immunotherapy. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839900.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


26. Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol; 2006 Aug 20;24(24):3844-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy.
  • RESULTS: The estimated 5-year failure-free survival (FFS) rate was 90% for patients with embryonal RMS (ERMS) stage 1, group I or IIa; stage 2, group I; or group III orbit.
  • The estimated 5-year FFS rate was 31% for patients with group III ARMS/UDS at unfavorable sites with regional lymph node disease, which is similar to metastatic RMS.
  • CONCLUSION: Patient and disease characteristics identify distinct subsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology Group to refine risk-adapted therapy assignment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Infusions, Intravenous. Male. Neoplasm Staging. Predictive Value of Tests. Prognosis. Risk Assessment. Risk Factors. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement